Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column-A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety

Tsutomu Yoshikawa, Akiyasu Baba, Makoto Akaishi, Yasuhisa Wakabayashi, Toshiaki Monkawa, Masafumi Kitakaze, Tohru Izumi, Hitonobu Tomoike

Research output: Contribution to journalArticle

9 Citations (Scopus)


Over the past few decades, several cardiac autoantibodies have been reported in sera from patients with dilated cardiomyopathy (DCM). Immunoadsorption (IA) therapy is one of the therapeutic tools to remove such autoantibodies. The objective of this study was to investigate functional effects of IA therapy using a tryptophan column in severe DCM patients. Of 49 patients enrolled, 44 were randomized from 10 sites in Japan. IA therapy was conducted in 40 patients with DCM (refractory to standard therapy for heart failure, New York Heart Association [NYHA] class III/IV, left ventricular ejection fraction [LVEF]

Original languageEnglish
JournalJournal of Clinical Apheresis
Publication statusAccepted/In press - 2016



  • Antibodies
  • Dilated cardiomyopathy
  • Heart failure
  • Immune system

ASJC Scopus subject areas

  • Hematology

Cite this